Stroke prevention in atrial fibrillation
Commentary regarding the AAN's evidence-based guideline update
Citation Manager Formats
Make Comment
See Comments

Atrial fibrillation is a common, potentially preventable cause of disabling stroke in the elderly, particularly in elderly women, resulting from embolism of stasis-precipitated thrombi formed in the left atrial appendage. In 1989, the first randomized clinical trial of anticoagulant therapy in atrial fibrillation showed that warfarin produced a large reduction in ischemic stroke.1 In the ensuing 25 years, more than 40 additional randomized trials have permitted stroke prophylaxis to be importantly refined. It has been a period of remarkable progress in stroke prevention. Here, we discuss selected aspects of the American Academy of Neurology (AAN)'s evidence-based guideline update.2
Footnotes
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
- © 2014 American Academy of Neurology
The Nerve!: Rapid online correspondence
- LETTER RE: Stroke prevention in atrial fibrillation: Commentary regarding the AAN's evidence-based guideline update
- Antonio Culebras, SUNY Upstate Medical University, Syracuse, NY, culebraa@upstate.edu
- Steven R. Messé, University of Pennsylvania and the Pennsylvania Hospital, Philadelphia
Submitted June 21, 2014
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Views & Reviews
Prevention of stroke in patients with nonvalvular atrial fibrillationRobert G. Hart, David G. Sherman, J. Donald Easton et al.Neurology, September 01, 1998 -
Special Article
Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillationReport of the Guideline Development Subcommittee of the American Academy of NeurologyAntonio Culebras, Steven R. Messé, Seemant Chaturvedi et al.Neurology, February 24, 2014 -
Articles
Independent predictors of stroke in patients with atrial fibrillationA systematic reviewThe Stroke Risk in Atrial Fibrillation Working Group et al.Neurology, August 06, 2007 -
Articles
Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillationHooman Kamel, J. Donald Easton, S. Claiborne Johnston et al.Neurology, September 19, 2012